New York, New York--(Newsfile Corp. - August 7, 2025) - OS Therapies (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) ...
Global warming has accelerated since 2015, according to a new study by the Potsdam Institute for Climate Impact Research (PIK). After accounting for known natural influences on global temperature, the ...
In the Phase 3 VISIONARY study, sibeprenlimab achieved a statistically significant and clinically meaningful 51.2% (P<0.0001) reduction in proteinuria at nine months of treatment when compared to ...
Global warming has accelerated since 2015, according to a new study by the Potsdam Institute for Climate Impact Research (PIK). After accounting for known natural influences on global temperature, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results